Considering the safety and efficacy aspects, TKD/IL-2 activated autologous NK cells have already been shown to have a favorable safety and efficacy profile in a phase II clinical trial in patients with advanced NSCLC (3). This evidence concerns the gene IL2 and non-small cell lung carcinoma.